Molecular insights into the role of MET in HPRCC informed the design of ongoing clinical trials such as SWOG1500 trial, which originally compared the VEGF inhibitor sunitinib to three different MET inhibitors (cabozantinib, crizotinib, and savolitinib) for the treatment of papillary RCC [20]. Here, MET is linked to papillary renal cell carcinoma.